The global blood-based biomarker for Alzheimer’s disease market is emerging as a transformative segment within the broader neurodiagnostics and precision medicine landscape. Alzheimer’s disease, a progressive neurodegenerative disorder, continues to impose a significant clinical, social, and economic burden worldwide. Traditional diagnostic approaches relying on cerebrospinal fluid (CSF) analysis and neuroimaging are often invasive, expensive, and limited in accessibility. In contrast, blood-based biomarkers offer a minimally invasive, scalable, and cost-effective alternative, enabling earlier detection, improved patient stratification, and better monitoring of disease progression. As healthcare systems increasingly emphasize early diagnosis and personalized treatment pathways, blood-based biomarker technologies are gaining rapid acceptance across clinical and research settings.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86889

Market Size and Growth
In 2024, the global blood-based biomarker for Alzheimer’s disease market was valued at US$ 127.4 Mn. Supported by robust research pipelines, rising diagnostic demand, and technological innovation, the market is projected to reach US$ 554.2 Mn by 2035. This expansion represents a strong compound annual growth rate (CAGR) of 14.3% from 2025 to 2035. The sustained growth trajectory reflects increasing investments in biomarker validation, regulatory progress toward clinical adoption, and the growing role of blood-based tests in large-scale population screening and pharmaceutical trials.

Market Segmentation
The market can be segmented based on biomarker type, technology platform, end user, and application. By biomarker type, key segments include amyloid beta, phosphorylated tau (p-tau), neurofilament light chain (NfL), and other emerging biomarkers that reflect neurodegeneration and synaptic dysfunction. Technology segmentation encompasses immunoassays, mass spectrometry, and next-generation ultra-sensitive platforms that allow detection of low-abundance proteins in blood. End users range from hospitals and diagnostic laboratories to research institutes and pharmaceutical companies, with applications spanning early diagnosis, disease monitoring, drug development, and clinical trial enrichment.

Regional Analysis
Geographically, North America dominates the global market, driven by advanced healthcare infrastructure, strong research funding, and early adoption of novel diagnostic technologies. The United States, in particular, benefits from a high prevalence of Alzheimer’s disease and an active biotechnology ecosystem. Europe represents another significant market, supported by government-backed dementia initiatives and collaborative research programs. Meanwhile, Asia Pacific is expected to witness the fastest growth over the forecast period, fueled by rising awareness, expanding geriatric populations, and increasing investments in diagnostic innovation across countries such as China, Japan, and South Korea.

Competitive Landscape
The global blood-based biomarker for Alzheimer’s disease market is moderately competitive, with a mix of established diagnostics leaders and innovative biotechnology firms. Key players include Biogen Inc., Beckman Coulter, Inc. (Danaher Corporation), Fujirebio, C2N Diagnostics, F. Hoffmann-La Roche Ltd, Quest Diagnostics, ALZpath Inc., Diagnostic BioSystems Inc., Quanterix, Novus Biologicals, Sysmex Corporation, Shimadzu Corporation, Alamar Biosciences, Inc., BGI Genomics, and Diadem srl. These companies are actively investing in research and development, strategic collaborations, and product commercialization to strengthen their market positions.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453